Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs VNET Group Inc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B), while VNET Group Inc trades at $5.26 (market cap $1.53B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 38× VNET Group Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and VNET Group Inc for 16 Days on average.
| TAK | VNET | |
|---|---|---|
Market Cap | $58.16B | $1.53B |
Volume | 2,467,530 | 3,847,582 |
Sector | Health | Technology |
52-Week High | $19.05 | $14.03 |
52-Week Low | $13.23 | $5.13 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $86.04B | $5.10B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VNET trades at $5.39, near a 52-week low with a bearish technical signal. The company reported a net loss of $256.77 million in 2025, with revenue of $9.95 billion, and negative profit margins. Recent news highlights a strategic investment closing and volatile options activity. Cash flow remains positive due to financing activities, but high leverage and negative earnings pose challenges.
Outlook is mixed: analyst consensus is moderately bullish (62.5% buy ratings), but fundamentals show persistent losses and high debt. Key risks include execution on AI infrastructure demand and balance sheet strain. The stock's appeal hinges on turnaround execution amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
